Orforglipron — Potential achievements
Products & Services · Potential achievementsEli Lilly Orforglipron — Potential achievements remained flat by 0.0% to $250.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric was flat by 0.0%, from $250.00M to $250.00M. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase in achieved milestones signals successful clinical development and a higher probability of future market entry, while delays or negative trial results signal increased risk to the long-term growth pipeline.
Detailed definition
This metric tracks the developmental progress, clinical trial milestones, and regulatory submission status for Orforglip...
Peer comparison
Comparable to late-stage pipeline development milestones for novel obesity or metabolic drug candidates at peer pharmaceutical companies.
lly_segment_orforglipron_potential_achievementsHistorical Data
| Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|
| Value | $250.00M | $250.00M | $250.00M | $250.00M | $250.00M | $250.00M | $250.00M | $250.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| YoY Change | — | — | — | — | +0.0% | +0.0% | +0.0% | +0.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's orforglipron — potential achievements?
- Eli Lilly (LLY) reported orforglipron — potential achievements of $250.00M in Q3 2025.
- How has Eli Lilly's orforglipron — potential achievements changed year-over-year?
- Eli Lilly's orforglipron — potential achievements decreased by 0.0% year-over-year, from $250.00M to $250.00M.
- What does orforglipron — potential achievements mean?
- This metric measures the clinical and regulatory progress of the oral GLP-1 drug candidate Orforglipron.